Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

33.3%

3 terminated/withdrawn out of 9 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

50%

3 of 6 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

N/A

5(62.5%)

Phase 2

2(25.0%)

Phase 4

1(12.5%)

8Total

N/A(5)

Phase 2(2)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT00678743Phase 4Completed

An Open-label Extension to Assess the Continued Efficacy of Omacor Plus Simvastatin

Role: collaborator

NCT00454493Not ApplicableCompleted

The Effect of Fish Oil Supplementation on Endothelial Function, Heart Rate Variability and Intimal Media Thickness of Patients With Coronary Artery Disease

Role: collaborator

NCT00569686Not ApplicableWithdrawn

Lovaza Therapy of Peripheral Arterial Disease

Role: collaborator

NCT00504309Not ApplicableCompleted

Vascular and Lipid Effects of Omega-3 Fatty Acids in People With Moderately Elevated Triglycerides

Role: collaborator

NCT00547716Not ApplicableWithdrawn

Use of Omega-3 Fatty Acids (Fish Oil) in Patients With Chronic Hepatitis C Infection

Role: collaborator

NCT00515541Phase 2Completed

Lovaza's Effect on the Activation of Platelets

Role: collaborator

NCT00517972Phase 2Withdrawn

Omacor for Perimenopausal Depression

Role: collaborator

NCT00794079Not ApplicableCompleted

Omega-3 Fatty Acids and Muscle Protein Synthesis

Role: collaborator

NCT00487591Completed

An Evaluation of Simvastatin Plus Omacor Compared to Simvastatin Plus Placebo in Subjects With Mixed Dyslipidemia

Role: collaborator

All 9 trials loaded